Propanc Biopharma plans first-in-human Phase 1b trial of PRP in up to 40 advanced solid tumor patients

• Propanc Biopharma began finalizing plans for a first-in-human Phase 1b study of PRP in up to 40 advanced solid-tumor patients.
• No clinical results were presented; initial safety and early activity findings are expected later, following trial start.
• The study is designed to assess whether PRP can be given safely, while providing early signals of anti-tumor effect.
• A feasibility review is underway across Australian trial centers ahead of a Clinical Trial Application targeted for Q4 2026.
• Avance Clinical will lead preparatory work, a step toward initiating the multi-center trial and starting GMP manufacturing this year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608180830PRIMZONEFULLFEED9811850) on August 18, 2026, and is solely responsible for the information contained therein.